ISTH 2021 Congress Archives - Page 2 of 91

Abstract Number: PB1163

C20209T Prothrombin Gene Mutation in a Caucasian Woman with a History of Venous Thrombosis

D. Jambou¹, N. Saut², V. Queyrel-Moranne³, A. Appert-Flory¹, F. Fischer¹, P. Suchon², P. Toulon¹
Abstract Number: PB0320

Calculation of Fresh Frozen Plasma Amount to Correct Prolonged International Normalized Ratio

L. Pinitsubsin¹, Y. Chinthammitr²
Abstract Number: OC 70.1

cAMP Prevents Antibody Induced Thrombus Formation in COVID-19

J. Zlamal¹, K. Althaus¹, H. Jaffal¹, H. Häberle², L. Pelzl¹, A. Singh¹, A. Witzemann¹, K. Weich¹, M. Bitzer³, N. Malek³, S. Göpel³, H. Bösmüller⁴, M. Gawaz⁵, V. Mirakaj², P. Rosenberger², T. Bakchoul^1,6
Abstract Number: PB1219

Can Combining a Risk Score Derived from Ubiquitous Biomarkers with a Clinical Risk Assessment Model Better Predict 90-day Post-discharge Hospital-associated Venous Thromboembolism among Medical Patients?

S. Woller^1,2, S. Stevens^1,2, J. Bledsoe^1,3, J. Lloyd¹, G. Snow¹, M. Fazili¹, L. Venner¹, J. Christensen¹, B. Horne^1,3
Abstract Number: PB0604

Can Plasminogen Activator Inhibitor 1 and Thrombin Activitable Fibrinolysis Inhibitor Explain Bleeding Phenotype in Hemophilia A?

S. Elhefnawy¹, M. Abd Elrehim², M. Elhawy².
Abstract Number: OC 65.1

Cancer is Associated with an Increased Stroke Risk in Patients with Atrial Fibrillation and CHA2DS2VASc Score ≤ 2

A. Leader^1,2, N. Mendelson Cohen³, S. Afek^2,4, R. Jaschek³, A. Frajman², O. Itzhaki Ben Zadok^5,2, P. Raanani^1,2, M. Lishner^6,2, A. Tanay³, G. Spectre^1,2
Abstract Number: PB0429

Cangrelor Long Term Prescription, Several Scenarios: A Case Report Series

O. Duranteau¹, L. Abdennour¹, M. Drir¹, F. Clarencon¹, V. Degos¹
Abstract Number: PB0838

Caplacizumab Rapidly Inhibits VWF-platelet Interaction: Pharmacodynamic Data from Healthy Volunteers and Patients with aTTP

F. Callewaert¹, J. Minkue Mi Edou², R. de Passos Sousa³
Abstract Number: LPB0049

Cardiovascular Outcomes in Patients with Essential Thrombocythemia: Analysis of the National Inpatient Sample (NIS)

G. Tafur¹, H. Saadaldin^2,3, F. Velazquez⁴, E. Marinescu⁵, A. Tafur^6,7
Abstract Number: PB1005

Case Report: Skin Necrosis in setting of Heparin and Warfarin Exposure

D.Z.S. Eng¹, C.P. Coorey¹, D. Hsu¹, S. Mallik¹
Abstract Number: OC 17.3

Case-fatality Rate of Major Bleeding Events among Patients Treated with Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-eluting Stent: A Systematic Review and Meta-analysis

T. Tritschler¹, A. Patel², N. Kraaijpoel³, P. Di Santo⁴, B. Hibbert⁴, G. Le Gal², L. Castellucci²
Abstract Number: PB0808

Catastrophic Thrombotic Syndrome in 8 Year Old Boy: Clinical Case Report

Y. Kashpurenko¹, K. Vilchevska¹, I. Bakhchyvandzhy¹
Abstract Number: PB0291

CATS-MICA Score in Predicting Venous Thromboembolism in SARS-CoV-2-infected Cancer Patients

D.S. Juliao Caamaño¹, C.L. Jimenez¹, C. Blanco Abad², J.L. Catoya Villa², A. Gutierrez ORtiz de la Tabla³, I. Aparicio Salcedo³, L. Ortega Moran³, M. Martin Jimenez³, A. Muñoz Martin³
Abstract Number: OC 42.2

Cellular Factor XIII in Macrophage Derived Foam Cells

L. Somodi¹, H. Bárdos², É. Katona¹, B. Baráth¹, G. Haramura¹, E. Horváth³, A.-H. Shemirani¹, L. Muszbek¹
Abstract Number: LPB0076

Cerebral Sinovenous Thrombosis and Asparaginase Re-exposure in Patients Aged 1 to 45 Years with Acute Lymphoblastic Leukemia: A NOPHO ALL2008 Study

M.T. Skipper¹, C.U. Rank^2,3, L. Andrés-Jensen⁴, K. Schmiegelow⁴, B.K. Albertsen^1,5, R. Tuckuviene^6,4, NOPHO Thrombosis and Haemostasis Working group
Abstract Number: PO171

Cerebral Thrombosis during Treatment of Childhood Acute Lymphoblastic Leukemia

A. Canbolat Ayhan¹
Abstract Number: PB0279

Change in Platelet Indices in Patients with Coronavirus Infection Disease (COVID-19): A Reflection of Platelet Activation and Contribution to Immunothrombosis?

M. Mezgebe¹, B.F. Jacobson¹, S. Louw¹
Abstract Number: PB0425

Changes in Plasminogen Binding and Cell Surface Properties in Streptococcus pyogenes in the Absence of Sortase A Are Due to Disruptions in Localization of M-protein

B. Russo^1,2, V. Ploplis^1,2, F. Castellino^1,2
Abstract Number: OC 65.2

Changes in Prescription Patterns of Oral Anticoagulants and Clinical Outcomes among Newly Diagnosed Non-valvular Atrial Fibrillation Patients in the Netherlands

Q. Chen¹, M.M. Toorop¹, S.C. Cannegieter¹, W.M. Lijfering¹
Abstract Number: PB0083

Changes in the Global Hemostatic Profile after Subarachnoid Aneurismatic Hemorrhage

K. Nanwani¹, I. Fernandez², E. Monzón², R. Justo², N. Butta², M. Quintana¹
Abstract Number: PB0529

Changes in Treatment Patterns in Patients with Severe Haemophilia – a Longitudinal Analysis of the Austrian Haemophilia Registry

D. Kraemmer¹, V. Ritschl², J. Rejtő¹, C. Feistritzer³, S. Gallistl⁴, S. Jäger⁵, N. Jones⁶, A. Kurringer⁷, P. Neumeister⁸, J. Rettl⁹, G. Schuster¹⁰, R. Schwarz¹¹, M. Sohm¹², W. Streif¹³, T. Schindl¹⁴, T. Stamm², K. Thom¹⁵, C. Male¹⁵, I. Pabinger¹, C. Ay¹
Abstract Number: PB0027

Changes in Vascular Physiology in Patients with End Stage Renal Disease Compared to Patients with ESRD and Concomitant Cardiovascular Disease

J. Goldstein¹, R. Dieter¹, K. Wieschhaus¹, J. Fareed¹
Abstract Number: PB1019

Charactering the Role of TLT-1 in Inflammatory Pathogenesis of Obesity and Nonalcoholic Fatty Liver Disease (NAFLD)

S. Branfield¹, B. Nieves Lopez², M. Poynter³, A.V. Washington¹
Abstract Number: PB0025

Characterisation of Patients with Peripheral Artery Disease at Increased Risk for Cardiovascular Events and Mortality

B. Kremers¹, J.-W. Daemen², H. ten Cate^1,2, H. Spronk¹, B. Mees², A. ten Cate-Hoek^1,2
Abstract Number: PB0755

Characteristics and Management of a Series of TAFRO Syndrome

X. Ye¹
Abstract Number: PB1091

Characteristics and Outcomes of Patients on Concurrent Direct Oral Anticoagulants and Targeted Anticancer Therapies – TacDOAC Registry

T.-F. Wang¹, L. Baumann Kreuziger², A. Leader^3,4, G. Spectre^3,4, M. Lim⁵, A. Gahagan⁶, R. Gangaraju⁶, K. Sanfilippo⁷, R. Mallick⁸, J. Zwicker⁹, M. Carrier¹
Abstract Number: PB0927

Characteristics and Treatment of Patients with von Willebrand Disease (VWD) in General Practice Settings in the United Kingdom

P. Du¹, K. Wilcox Hagberg², S. Tzivelekis³, F. Truong Berthoz⁴, G. Özen⁵, S. Jick^2,6
Abstract Number: PB0486

Characteristics of Anti-drug Antibody against Emicizumab Analyzed Using Hemophilia A Patient-derived Plasma Samples

R. Kawasaki¹, M. Kaneda², M. Noguchi¹, N. Matsumoto¹, H. Abe¹, Y. Tashiro¹, Y. Inokuchi¹, H. Yasuno¹, T. Soeda¹, Y. Yoshimura¹, T. Oka²
Abstract Number: LPB0125

Characteristics of Pediatric Oncology Patients with Tumour Thrombus

N. Samji¹, A.F. Fajardo¹, A.K. Chan¹, M.D Bhatt¹
Abstract Number: OC 31.4

Characterization of a New Family with Lifelong Macrothrombocytopenia Caused by a Novel Nonsense Variant in TPM4

A. Marín-Quílez¹, C. Fernández-Infante¹, M.Á. Manrique Gonzalo², C. Llorente-González¹, M. Millán-Salanova¹, S. Santos-Mínguez¹, C. Miguel-García¹, I. Rodríguez-Iglesias¹, F. López-Cadenas², T. González², V. Palma-Barqueros³, R. Benito¹, M. Díez-Campelo², J.R. González-Porras², J.M. Hernández-Rivas^1,2, M. Vicente-Manzanares¹, J. Rivera^3,4, J.M. Bastida^2,4
Abstract Number: LPB0052

Characterization of Andexanet Alfa-associated Heparin Resistance: Implications for Management

N. Thalji¹, C. Chabata², P. Patel³, B. Sullenger², R. Camire⁴
Abstract Number: OC 52.2

Characterization of the Role of Integrin α5β1 in Platelet Function, Haemostasis and Arterial Thrombosis in Mice

E. Janus-Bell¹, A. Yakusheva^1,2, N. Receveur¹, U.M. Ahmed¹, C. Mouriaux¹, C. Bourdon¹, M.A. Panteleev², C. Gachet¹, P.H. Mangin¹
Abstract Number: LPB0042

Characterization of Thrombotic Risk in Patients with Cancer

J. Trujillo Santos¹, M. Salgado², I. García Escobar³, R. Molina⁴, A. Araújo⁵, E. Horváth⁶, R. Porta⁷, J.C. Benítez⁸, M. Lobo⁹, E. Martí¹⁰, F. Garicano¹¹, M. Malheiro¹², A.L. Costa¹³, A.C. Albuquerque¹⁴, M.J. Ribeiro¹⁵, B. Campos Balea¹⁶, A. Cañada Martínez¹⁷, E. Brozos¹⁸, M. Masvidal¹⁹, P. Cerezuela²⁰, CARTAGO study group
Abstract Number: PB0752

Chemotherapy Induced Thrombocytopenia: Is it Inducing Additional Social, Economic and Clinical Burden?

N. Anwar¹, N. Fatima¹, H.-u.- Mujtaba¹, T. Shamsi¹
Abstract Number: PB0757

Chemotherapy-induced Thrombocytopenia and Platelet Transfusions in Hematology/Oncology Practice

L. Hambardzumyan^1,2, A. Movsisyan^1,2, M. Badikyan^2,3, N. Martirosyan^2,3, H. Khachatryan^1,2, A. Sevoyan², H. Grigoryan^1,1,2, N. Martirosyan^2,4, G. Tamamyan^1,2,4, S. Danielyan²
Abstract Number: PB0782

Children with Bleeding and Clotting Disorders: Reviewing Quality of Life Tools

S. Jones^1,2, J. Bushe¹, H. David¹, C. Dinh¹, K. Kolosidhi¹, D. Rai¹, F. Newall^2,1
Abstract Number: OC 53.2

Children with Hereditary Thrombotic Thrombocytopenic Purpura (hTTP) Have a High Incidence of Acute Episodes: Data from the International Hereditary TTP Registry (IHTTP Registry)

E. Tarasco^1,2, K. Sakai³, S. Al Shanbary⁴, L. Bütikofer⁵, Y. El Chazli⁶, J.N George⁷, H. Hengartner⁸, S. Jalal⁹, P.N Knöbl¹⁰, E. Maaß¹¹, S. Milanovich¹², S. Perungo¹³, G. Sinkovits¹⁴, M. Steele¹⁵, A.S. von Krogh^16,17, K. Wyatt¹⁸, B. Lämmle^1,19, J.A. Kremer Hovinga^1,2, other members Steering Committee international hTTP Registry
Abstract Number: PB0607

Chinese Real-world Experience of Product Switching in Severe Hemophilia Patients: from rFVIII-FS(Kogenate®) to BAY 81-8973 (Kovaltry®)

C. Rong¹, Z. Shiqiu¹, G. Hua¹, L. Jia¹, G. Jing¹, Y. Ming², Z. Hong², Y. Lin², Z. Xin³
Abstract Number: LPB0132

Chronic Edible Dosing of Δ9-tetrahydrocannabinol (THC) in Non-human Primates Reduces Systemic Platelet Activity and Function

S.E. Reitsma¹, J. Johnson¹, J. Pang¹, I. Parra-Izquierdo^1,2, H. Hara Sudhan Lakshmanan¹, A.R. Melrose^2,1, M. T. Hinds¹, J.E. Aslan^2,1, O.J. McCarty¹, J.O. Lo³
Abstract Number: PB0756

Chronic Myeloid Leukemia with Extreme Thrombocytosis as Unusual Initial Presentation

N. Petkova¹
Abstract Number: PB0311

Circulating Biologic Markers of Endothelial Dysfunction in Chronic Myeloproliferative Neoplasms

O. Smirnova¹, N. Silina¹, N. Korsakova¹, O. Golovina¹, E. Efremova¹, M. Fominykh¹, S. Voloshin¹, L. Papayan¹
Abstract Number: PB0294

Circulating Biologic Markers of Endothelial Dysfunction in COVID-19 Patients

O. Matvienko¹, N. Korsakova¹, O. Smirnova¹, A. Lerner², T. Shwedova², O. Golovina¹, L. Papayan¹
Abstract Number: LPB0103

Circulating Cellular Clusters Are Correlated with Thrombotic Complications and Clinical Outcomes in COVID-19

A. Dorken Gallastegi¹, L. Naar¹, E.M. Van Cott¹, R.P. Rosovsky¹, D.J. Gregory¹, D. Annamalai², J. Lee¹, H.M.A. Kaafarani¹, G. Velmahos¹, R.G. Tompkins¹, G.H. Frydman^1,2
Abstract Number: PB1119

Circulating Extracellular Vesicles in Patients with Cancer and Venous Thromboembolism: A Systematic Review and Meta-analysis

O. Varol^1,2, D. Burger^1,2, T. Tritschler³, P. Wells⁴
Abstract Number: PB0164

Circulating Histones Are Associated with Disease Severity and Coagulopathy in COVID-19

R.J Shaw¹, J. Austin¹, J. Taylor², T. Dutt², G. Wang¹, S.T Abrams¹, C.-H. Toh¹
Abstract Number: OC 68.2

Circulating Levels of Platelet, Endothelial and Red Blood Cell Microvesicles in COVID-19: Association with Biomarkers of Coagulation, Fibrinolysis and Angiogenesis

M.S. Barbosa¹, F. Lima¹, C.R.P. Moraes¹, I.P. Santos², I.T. Borba Junior¹, S.C. Huber², S.A.L. Montalvao², J.M. Annichino-Bizzacchi^1,2, A. C. Palma¹, R. G. Ulaf¹, A.F. Bernardes¹, E. Mansour¹, M.L. Moretti¹, L.A. Velloso^1,3, E.V. De Paula^1,2
Abstract Number: PB0268

Circulating Nucleosome Immunoassay: Evaluating a Clinically-applicable Test to Risk Stratify COVID-19 and Target Anticoagulation

C. Rea¹, S. Napoli¹, S. Mujib¹, F. Trovato¹, A. Zamalloa¹, J. Smith¹, D. Nagra¹, K. O'Gallagher¹, M. McPhail¹
Abstract Number: OC 31.2

Clinical and Biological Assessment of the Largest Family with SRC-RT due to p.E527K Gain-of-Function Variant

N. Revilla¹, V. Palma-Barqueros², A. Galera³, C. Zaninetti⁴, N. Bohdan², A. Rodriguez-Alén⁵, A. Sánchez-Fuentes², A. Marin-Quilez⁶, A. Zamora-Canovas², V. Vicente², A. Greinacher⁴, M.L. Lozano², J.M. Bastida^6,7, J. Rivera^2,7
Abstract Number: LPB0080

Clinical and Biological Assessment of the Second Pedigree Affected with X-linked GATA-1 Related Thrombocytopenia and Blood Group Lutheran Null

A. Rodriguez-Alén¹, V. Palma-Barqueros², N. Rollón-Simón¹, N. Revilla³, N. Bohdan², J. Padilla², A. Zamora-Cánovas², A. Marín-Quílez⁴, A. Sánchez-Fuentes², J.R. González-Porras⁴, V. Vicente², J. Cuesta¹, M.L. Lozano², J.M. Bastida^4,5, R. Pozo^2,5
Abstract Number: PB0693

Clinical and Genetic Analysis of Nine Cases of Hereditary Factor V Deficiency

D. Zhang¹, X. Zhang², R. Yang¹
Abstract Number: PB1158

Clinical and Molecular Characterization of Chinese Patients with Protein S deficiency

X. Zhang¹, D. Zhang², R. Yang², F. Zhou¹
Abstract Number: PB0409

Clinical and Molecular Characterization of Iranian Patients with Congenital Qualitative Fibrinogen Disorders

S. Mohsenian¹, A. Azarkeivan¹, M. Mirakhorli², M. Jazebi², O. Seidizadeh³.
Abstract Number: PB0646

Clinical and Pharmacokinetic Assessment after Switching to an Extended Half-life Product for Prophylaxis in Haemophilia B

K.I. Álvarez Tosco¹, M.Á. Ocaña Gómez¹, A.M. Ríos de Paz¹, M.D. De Dios García¹, M.C. Mesa Lorenzo¹, J. Merino Alonso¹
Abstract Number: PB0873

Clinical Application of Genetic Testing in Patients with Not Acquired Thrombocytopenia: One Center Experience

P. Silva de Tena¹, M. Argüello-Tomás¹, C. Pascual Izquierdo^1,2,3, J.L. Díez-Martín^1,2,3, C. Martinez Laperche^1,2,3, G. Perez Rus^1,2,3
Abstract Number: PB0629

Clinical Assessment with the Evaluation of Joint Disease and Haemostatic Treatment in Patients with Severe Haemophilia B

A. Buczma¹, E. Odnoczko², B. Baran², A. Gwozdowska¹, J. Zawilski³, J. Windyga¹
Abstract Number: PB0473

Clinical Characteristics and Incidence of Inhibitors in Previously Untreated Children with Haemophilia: An Update of the Hemfil Cohort Study

L.L. Jardim^1,2, M. Antônio Portugal Santana3³, D. Gonçalves Chaves⁴, L. Werneck Zucheratto¹, M. Hermida Cerqueira⁵, C. Santos Lorenzato⁶, V. Franco⁷, J. van der Bom², S. Meireles Rezende¹
Abstract Number: OC 44.1

Clinical Characteristics and Prognosis of Antiphospholipid Syndrome Patients Based on Cluster Analysis: A 10-year Cohort Study

W. Qi¹, J. Zhao^1,2, X. Tian^1,2, M. Li^1,2, X. Zeng^1,2
Abstract Number: PB0433

Clinical Characteristics of Acquired Haemophilia A Patients in 5 European Countries

I. Palau¹, S. Brown¹, A. Rosli², E. Seth²
Abstract Number: PB0260

Clinical Course of COVID-19 in Patients with Inherited Bleeding Disorders: An Interim Analysis of 28 Cases

A. Sikorska¹, E. Stefanska-Windyga², J. Windyga¹
Abstract Number: PB1051

Clinical Course of Thrombotic Antiphospholipid Syndrome with Positive IgA Anticardiolipin or IgA β2-glycoprotein I

L. Figueiredo¹, B. Mazetto², A.P. dos Santos², B. Jacintho², C. Vaz², J.D. Oliveira³, G. Mesquita², J. Annichino-Bizzachi², F. Orsi²
Abstract Number: PB0775

Clinical Factors Predicting Decrease in Hemoglobin Levels during Preoperative Autologous Blood Donation by Patients Undergoing Major Orthopedic Surgery

S. Fujii¹, Y. Watanabe¹, A. Ito¹.
Abstract Number: PB0287

Clinical Impact of Immune Thrombocytopenic Purpura in the Context of SARS-CoV-2 Infection

C. Tarniceriu^1,2, L.L. Hurjui³, L. lozneanu², C. Delianu⁴, I. Hurjui⁵
Abstract Number: PB1185

Clinical Implications of V/Q SPECT Scans Being Inconclusive in 20% of Patients Referred on Suspicion of Pulmonary Embolism

K. Medson¹, A. Hassler², R. Taeri², M. Bagge³, P. Lindholm¹, E. Westerlund¹
Abstract Number: PB1216

Clinical Observations in Patients with Cerebral Venous Sinus Thrombosis

T.W Htut¹, H.G Watson¹, G. Mackay², M.M Khan¹
Abstract Number: PB0508

Clinical Outcomes after Joint Surgery in Patients on Turoctocog Alfa Pegol Prophylaxis

A. Tiede¹, S. Shivamurthy², P. Chowdary³
Abstract Number: PO116

Clinical Outcomes and Natural History of Critical Limb Ischemia: A Real World Experience

D. Ceccato¹, S. Ragazzo¹, F. Boscaro¹, F. Ceccato¹, G. Camporese¹, G. Avruscio¹
Abstract Number: OC 67.3

Clinical Outcomes in Adults with Hemophilia B with and without Pre-existing Neutralizing Antibodies to AAV5: 6 Month Data from the Phase 3 Etranacogene Dezaparvovec HOPE-B Gene Therapy Trial

F.W. Leebeek¹, W. Miesbach², M. Recht³, N.S Key⁴, S. Lattimore³, G. Castaman⁵, E.K Sawyer^6,7, D. Cooper^6,7, V. Ferriera^6,7, S.W Pipe⁸, HOPE-B Investigators
Abstract Number: PB0195

Clinical Outcomes of Prophylactic vs. Therapeutic Doses of Anticoagulation In COVID-19 Patients: A Systematic Review and Meta-analysis

M.A. Elsebaie¹, B. Baral¹, T. Shrivastava¹, M.J. Tariq¹, D. Kumi¹, M. Elsebaie²
Abstract Number: PB0492

Clinical Profile and Bleeding Outcome of Pediatric Hemophilia A: The Royal Hospital’s Experience, Oman

A. Al Rawahi¹, F. Al Riyami², I. Al Ghaithi³, H. Al Shukaili⁴, M. Al Abri⁴, A. Al Rawahi⁵
Abstract Number: PB0717

Clinical Profile and Bleeding Outcome of Pediatric Rare Bleeding Disorders: The Royal Hospital’s Experience, Oman

M. AL Saadi¹, H. AL Hasani¹, A. Al Roshdi¹, A. Al Amri¹, I. Al Ghaithi²
Abstract Number: PB0314

Clinical Relevance of JAK2V617F on Patients with Philadelphia-negative Myeloproliferative Neoplasms

R. Frikha¹, H. Kamoun¹
Abstract Number: PB1114

Clinical Risk Factors for Venous Thromboembolism in Hematologic Malignancies

A. López Sacerio¹, N. Alvarez Basulto², M. Acosta Alvarez¹, M.C. Tejeda Ramón¹
Abstract Number: PB0654

Clinical Translatable Preconditioning for Platelet Gene Therapy in Murine Hemophilia A with Inhibitors

Y. Chen^1,2, J. Schroeder¹, J. Li^1,2, W. Jing¹, J. Hu², Q. Shi¹
Abstract Number: OC 62.2

Clinical Value of Early Assessment of Hyperfibrinolysis by Rotational Thromboelastometry during Postpartum Hemorrhage for the Prediction of Severity of Bleeding: A Multicenter Prospective Cohort Study in the Netherlands

M. Tahitu^1,2, P. Ramler^1,2, A. Gillissen^1,3,2, C. Caram-Deelder^3,2, D.D. Henriquez^3,1,2, M.P. de Maat⁴, J.J Duvekot⁵, J. Eikenboom⁶, K.W. Bloemenkamp⁷, T. van den Akker^1,8,9, J.G van der Bom^2,3
Abstract Number: PB0923

Clinical, Economic, and Quality of Life Burden Associated with von Willebrand Disease (VWD) in Adults and Children: Systematic and Targeted Literature Reviews

G. Castaman¹, N. Jansen², S. Santos², E. Berntorp³
Abstract Number: LPB0118

Clinically Meaningful and Long-term Improvements in Fatigue with the C3 Inhibitor Pegcetacoplan In Paroxysmal Nocturnal Hemoglobinuria: Post-hoc Analyses from the PEGASUS Study Week 48

D. Cella¹, S.P. Sarda², R. Hsieh³, J. Fishman², Z. Hakimi⁴, K. Cutts³, W.R. Lenderking⁵
Abstract Number: PB1063

Clinico-pathologic Characterization of Patients Tested for Antiphospholipid Syndrome at a Tertiary Care Hospital

K. Sajeeve¹, D. K.V¹, V. V¹, A. Catherine Jacob¹, D. Sidharth¹, D. Vidyadharan¹
Abstract Number: PB0611

Clinicopathological Parameters and Influence of Blood Group and von Willebrand Factor (vWF) Levels on Residual Factor VIII (FVIII) Levels in Haemophilia A Patients

D. Ray¹, N. Kumar¹, J. Ahluwalia¹, R. Das¹, C. Hans¹, A. Jain¹, P. Malhotra¹, D. Bansal¹
Abstract Number: PB0426

Co-delivery of Tissue Plasminogen Activator and Plasminogen Using Magnetically Powered Microwheels

D. Disharoon¹, D. Marr¹, K. Neeves²
Abstract Number: PO177

Coagulation Abnormalities At Presentation of Childhood Acute Lymphoblastic Leukemia

A. Canbolat Ayhan¹
Abstract Number: PB0108

Coagulation Abnormalities in Patients without Congenital Bleeding Disorders: Analysis of Secondary Causes of Low Clotting Factors Levels

A. Lorenzo Jambrina¹, M. Mosquera Tapia¹, A. Torres Tienza¹, E. Zato Hernández¹, V. Cardos Gómez¹, P. Galán Álvarez¹, C. Olivier Cornacchia¹, J.A. Queizán Herández¹
Abstract Number: PB0110

Coagulation Activity of Circulating Microparticles in Patients with Cardiovascular Diseases

A. Mazurov¹, I. Zyuryaev¹, A. Komarov¹, T. Martynyuk¹, N. Golubeva¹, O. Antonova¹
Abstract Number: PB0977

Coagulation and Anticoagulation Factors Affecting Platelet Responses Independently of Thrombin and Fibrin

I. De Simone^1,2, J.M. Gibbins², H. ten Cate^1,3, J.W. Heemskerk¹, C.I. Jones², P.E. van der Meijden^1,3
Abstract Number: LPB0071

Coagulation Factor 5 (F5) Is an Estrogen-responsive Gene in Breast Cancer Cells

M. Seierstad Andresen¹, M. Sletten¹, P.M. Sandset^2,1, N. Iversen¹, B. Stavik*¹, M. Tinholt*¹
Abstract Number: OC 77.2

Coagulation Factor XII Signaling via uPAR- β1 Integrin Promotes Renal Tubular Senescence in Diabetic Nephropathy

A. Elwakiel¹, K. Shahzad¹, I. Gadi¹, D. Gupta¹, R. Rana¹, S. Kohli¹, T. Renné², B. Isermann¹
Abstract Number: PB1197

Coagulation Factors Levels during and after Anabolic Androgenic Steroid Use: Data from the HAARLEM Study

E. Camilleri¹, D.L. Smit², N. van Rein^1,3, S. Le Cessie¹, O. de Hon⁴, M. den Heijer⁵, S.C. Cannegieter^1,6, W. de Ronde²
Abstract Number: PB0084

Coagulation Management Strategies in Cardiac Surgery: Viscoelastic tests

I. Rodriguez Martin¹, Isabel Rodriguez Martin
Abstract Number: PB0035

Coagulation Potential, Electrophysiological Characteristics and Structural Remodeling due to Atrial Fibrillation in Young and Aged Goats

E. D'Alessandro¹, B. Scaf², V. Sobota², A. van Hunnik², M. Kuiper², J. Winters², R. van Oerle¹, H. Spronk¹, F. van Nieuwenhoven², H. ten Cate¹, S. Verheule², U. Schotten²
Abstract Number: LPB0024

Coagulation-cancer Crosstalk; Von Willebrand Factor Contributes to Pro-invasive and Pro-angiogenic Properties in Breast Cancer Cells

S. Patmore¹, S. Pal Singh Dhami¹, J. Castle², C. C. Kirwan^2,3, J. S. O'Donnell¹, J. M. O'Sullivan¹
Abstract Number: PB0740

Coagulopathy in Multiple Myeloma

K. Chasakova¹, L. Slavik², D. Starostka¹, J. Úlehlová², T. Papajik², J. Minařík²
Abstract Number: PB0232

Coagulopathy in Patients with Severe COVID-19

R. Cacciola¹, E. Gentilini Cacciola², V. Vecchio³, E. Cacciola¹
Abstract Number: PO148

Cocktail of Inherited Hemostatic and Red Cell Disorders in Unrelated Families of Interior Sindh

A. Naz¹, M. Khanzada²
Abstract Number: PB1046

Collagen Turnover Biomarkers in Atrial Fibrillation and their Use in Clinical Management and the Study of Inflammatory Pathogenesis

K. Wieschhaus¹, E. Bontekoe¹, J. Fareed¹, D. Hoppensteadt¹, S. Mushabbar¹, J. Goldstein¹
Abstract Number: PB1031

Combined Antiplatelet Therapy Reduces the Pro-inflammatory Properties of Activated Platelets

A.C. Heinzmann¹, D.M Coenen¹, T. Vajen¹, J.M. Cosemans¹, R.R Koenen¹
Abstract Number: PB0009

Combined Focused Ultrasound and Electrohydraulic Shock Wave Thrombolytic Therapy Accompanied by Tissue Plasminogen Activator Administration Reduce Thrombus Content in the Arterial Atherothrombotic Stenosis

H. Mehrad^1,2, A. Foletti^3,2
Abstract Number: PB0301

Combining Artificial Neural Networks and Blood Tests to Diagnose Covid-19 Infection

T.D. Martins¹, S.D. Martins², S.A.L. Montalvão², M. Al Bannoud¹, G.Y. Ottaiano¹, L.Q. Silva², S.C. Huber², T.S.P. Diaz³, C.K. Wroclawski⁴, C.C. Filho⁴, R.M. Filho⁵, J.M. Annichino-Bizzacchi²
Abstract Number: PB0051

Combining Heparin with a FX/FXa Aptamer to Reduce Thrombin Generation in Models of Cardiopulmonary Bypass and COVID-19 Associated Coagulopathy

C.V. Chabata^1,2, J.W. Frederiksen¹, L.B. Olson^2,3, I.A. Naqvi⁴, B.A. Sullenger¹
Abstract Number: PB1013

Common Cardiovascular Disease Polygenic Risk Scores for Arterial and Venous Disease Influence Different Platelet Reactivity Tests

J. Grech¹, M. Chan^1,2, A. Lachapelle¹, F. Thibord¹, Z. Schneider¹, P. Armstrong², C. Wallace de Melendez¹, T. Warner², M.-H. Chen¹, A. Johnson¹
Abstract Number: PB0379

Comparability of PT Determination with STA-NeoPTimal on STart and STart Max Semi-automated Instruments

G. Le Goff¹, M. Bouchain¹, A. Carlo², J. Beltran¹
Abstract Number: OC 56.2

Comparative Analysis of Residual Factor VIII Expression from Recurrent F8 Nonsense Mutations Indicates that Localization in the B-domain Favours Readthrough-mediated Protein Output

M.F. Testa¹, S. Lombardi¹, M. Ferrarese¹, P. Radossi², D. Belvini², G. Castaman³, F. Bernardi¹, M. Pinotti¹, A. Branchini¹
Abstract Number: PB1083

Comparative Effectiveness of Alternative Bridging Therapies for Subtherapeutic INR in Patients with Left Ventricular Assist Devices

G. Chung¹, E. Salem², E. Sippola³, S. Shore³, L. Baumann Kreuziger², G. Barnes³
Abstract Number: PB1250

Comparative Effectiveness of Oral Anticoagulants in Venous Thromboembolism: On-treatment Analysis in GARFIELD-VTE

S. Haas¹, H. Bounameaux², A.E. Farjat³, W. Ageno⁴, J.I. Weitz⁵, S.Z. Goldhaber⁶, A.G.G. Turpie⁷, S. Goto⁸, P. Angchaisuksiri⁹, P. MacCallum^3,10, H. Ten Cate¹¹, E. Panchenko¹², M. Carrier¹³, C.J. Sanchez Dias^14,15, H. Gibbs¹⁶, P. Jansky¹⁷, G. Kayani³, S. Schellong¹⁸, P. Prandoni¹⁹, A.K. Kakkar^3,20, on behalf of the GARFIELD-VTE investigators
Abstract Number: PB0471

Comparative Recovery of FVIII Antigen with Various FVIII Therapeutic Concentrates Using an Improved 2^nd Generation ELISA Kit

R. Ni¹, P. Erb¹, J. Della Maestra¹, H. Atkinson², D. Foulon¹, K.M Black³, H. Hoogendoorn¹, D. Matino^2,4
Abstract Number: PB0633

Compare the Efficacy and Safety of Low-dose and Intermediate-dose Prophylactic Therapy in Adult Patients with Severe Hemophilia A, a Self-control Study

h. 高华¹, R. Chen¹, S. Zhou¹
Abstract Number: PB1177

Comparing “Clinical Hunch” against Clinical Decision Scores (PERC Rule, Wells Score, Revised Geneva Score, YEARS Criteria) in Acute Pulmonary Embolism Diagnostics

K. Medson¹, J. Yu², L. Liwenborg¹, E. Westerlund¹, P. Lindholm¹
Abstract Number: PB1222

Comparing Adherence of Low Molecular Weight Heparin versus Unfractionated Heparin for Thromboprophylaxis of Medical Inpatients

M. Trybula¹, Z. Ahart¹, E. Stacy²
Abstract Number: PB0047

Comparing the Real-world and Clinical Trial Bleeding Rates Associated with Anticoagulation Treatment for Atrial Fibrillation

R. Buderi¹, A. Yi², P. Allen¹, T. Bebi¹, C. Vigna¹, R. Jain¹, A. Majumdar¹, D. Bloomfield², J. Salter², D. Freedholm², A. Galaznik¹
Abstract Number: PB0390

Comparison between Coagulation Factor Deficiencies versus Pharmacological Inhibition of Activated Coagulation Factors Using Clot Waveform Analysis

Y. Fujimori¹, M. Wakui², H. Katagiri¹, Y. Ozaki¹, Y. Kondo¹, S. Oka¹, T. Nakagawa¹, S. Nakamura¹, M. Murata²
Abstract Number: PB1218

Comparison of 0.9% Normal Saline (NS) Flush and Unfractionated Heparin (UFH) Flush for Maintenance of Central Venous Catheter Line Patency

A.N. Landmesser^1,2, R.J. Roberts², R.P. Rosovsky^3,4, M.E. Barra²
Abstract Number: PB0101

Comparison of a Chromogenic vs. APTT-based Factor VIII Activity Assay in the Recovery of a Pegylated Factor VIII Replacement Therapy in Plasma Samples

T. Quinton¹, J. Fraser¹, K.M Black¹, A. Sadeghi-Khomami¹
Abstract Number: OC 45.2

Comparison of Alternative Viscoelastic Hemostatic Assays – Rotational Thromboelastometry versus Sonorheometry for Rapid Diagnosis in Trauma Patients: An Interim Analysis

J.M. Wohlgemut¹, A. Rossetto¹, R. Davenport¹
Abstract Number: LPB0015

Comparison of D-dimer values at peak and trough concentrations of direct oral anticoagulants: result of D-dimer testing is not affected by plasma drug concentration

S. Margetić¹, I. Ćelap¹, M. Razum¹, R. Mihić¹, S. Šupraha-Goreta²
Abstract Number: PB0344

Comparison of Peak Plasma Concentrations of Apixaban in Adolescent and Adult Patients

I. Celap¹, S. Margetic¹, J. Obuljen², J. Lenicek Krleza², I. Linarić², M. Razum¹, R. Mihic¹
Abstract Number: PB0348

Comparison of Platelet Counts Using Impedance, Optical and CD61-immunoplatelet Methods in Thrombocytopenic Patients

T. Nguyen¹, P.-L. Tran², T. Tran¹, T. Nguyen¹, T. Nguyen¹
Abstract Number: PB0004

Comparison of Platelet Function Tests during P2Y₁₂ Inhibition

P.P. Wadowski¹, J. Pultar¹, C. Weikert¹, B. Eichelberger², I.M. Lang³, R. Koppensteiner¹, S. Panzer², T. Gremmel^1,4
Abstract Number: PB0368

Comparison of PT/INR Assessment with STA-NeoPTimal on an Automated and Semi-automated Test Platform

S. Savigny¹, F. Depasse², A. Veyradier³
Abstract Number: PB1263

Comparison of Real-world Effectiveness and Safety of Enoxaparin versus Tinzaparin or Dalteparin in Cancer Patients with Venous Thromboembolism. The RIETECAT Cohort Study

M. Monreal¹, J. Trujillo-Santos², D. Farge-Bancel³, J.M. Pedrajas⁴, C. Gómez-Cuervo⁵, A. Ballaz⁶, A. Braester⁷, I. Mahé⁸
Abstract Number: PB0730

Comparison of the Relative PAR1, PAR2 and PAR3 Cleavage Profiles by Thrombin, APC, Factor Xa and Factor VIIa

A. Yamashita^1,2, M. Taki², J.H. Griffin¹, L.O. Mosnier¹
Abstract Number: PB0383

Comparison of Visual Interpretation of the DOAC Dipstick Test with a Reader System for Rapid and Accurate Detection of Direct Oral Anticoagulants in Neurology and Cardiology – Interim Data from a Prospective Consecutive Comparative Study

S. Margetić¹, I. Ćelap¹, D. Delić-Brkljačić², J. Harenberg^3,4, A. Lovrenčić-Huzjan⁵, P. Mioč⁶, S. Šupraha Goreta⁷
Abstract Number: PB0617

Comprehensive Genotype Characterization in Non-severe Hemophilia A. Mutational Profile and Assessment of the Bleeding Phenotype in Argentine Patients

L. Rossetti¹, A.I. Woods², A. Blanco³, J. Paiva³, V. Marchione¹, C.P. Radic¹, M.M. Abelleyro¹, B. Ziegler¹, K. Waisman¹, M.L. Romero³, M.M. Casinelli³, A. Sánchez-Luceros^2,3, C. De Brasi^1,4
Abstract Number: PB1132

Concurrent Atypical Thrombotic Complications of Acute Promyelocytic Leukemia (APL) in an Anticoagulated Patient: A Rare Case Report

A. Ashwath¹, A. Cordova Sanchez¹, S. Rao¹, R. Denley¹
Abstract Number: PB0690

Concurrent Use of Tranexamic Acid and Hormonal Therapy: Management of Heavy Menstrual Bleeding in Women with Inherited Bleeding Disorders

A. Epstein¹, O. Turan¹, R. Abdul-Kadir¹
Abstract Number: PB0935

Congenital Bleeding Disorders in Adolescent Females Evaluated for Menorrhagia and Iron Deficiency Anemia

A. Trillo¹, R. Leeman¹, J. Davis², F.F. Corrales-Medina²
Abstract Number: PB0716

Congenital Factor Vii Deficiency and Vacterl Association: An Unusual Combination

A. Ramirez¹, C. Lince-Rivera¹, L. Florez¹, A. Infante¹, Y. Vargas¹
Abstract Number: PB0704

Congenital Factor XI Deficiency: A Single-center Retrospective Analysis of 80 Cases

X. Wang^1,2,3, D. Zhang^1,4, X. Liu¹, F. Xue¹, W. Liu¹, Y. Chen¹, R. Fu¹, L. Zhang^1,2,3, R. Yang^1,2,3
Abstract Number: PB0644

Consistency Analysis and Data Validation Regarding Hospitalization among Hemophilic Patients from the Hemophilia Center of the Hematology Service of HC FMUSP – (2008-2018)

A.C. Guersoni¹, P. Villaça², V. Rocha², E. Trindade³, O.D. Luiz⁴
Abstract Number: OC 64.1

Contact Activation and Coagulation in Residual Venous Obstruction

A.F. Iding^1,2, B. Kremers², M. Nagy², A. Pallares Robles^2,3, R. van Oerle², H. ten Cate^1,2,4, H.M. Spronk², A.J. ten Cate-Hoek^1,2
Abstract Number: PB0141

Contact System and Intrinsic Pathway Are Activated and Associated with Clinical and Laboratory Outcomes in COVID-19 Patients

M.W Henderson^1,2, F. Lima³, C.R.P. Moraes³, A. Ilich^2,4, S. Huber⁵, S.A.L. Montalvao⁵, M.S. Barbosa³, A.C Palma³, R.G Ulaf³, L.C. Ribeiro³, A.F. Bernardes³, M.L. Moretti³, S. Strickland⁶, J.M Annichino-Bizzacchi^3,5, F.A. Orsi³, E. Mansour³, L.A Velloso^3,7, N.S Key^1,2,4, E.V De Paula^3,5
Abstract Number: PB0094

Control of Anti-coagulant Treatment in Patients with Acute Stroke by the Results of the «Thrombodynamics» Test

E. Klychnikova¹, G. Ramazanov¹, E. Tazina¹, S. Abudeev¹, A. Vyshlova¹
Abstract Number: OC 42.3

Controlled Knockdown of Fibrinogen with siRNA Modulates Fibrinogen-mediated Inflammation

L.J. Juang^1,2,3, W.S. Hur⁴, L.M. Silva⁵, A.W. Strilchuk^1,2,3, J. Leung^1,2,3, B. La Prairie³, J.P. Luyendyk⁶, P.R. Cullis³, T.H. Bugge⁵, M.J. Flick⁴, C.J. Kastrup^1,2,3
Abstract Number: OC 02.2

Controlled Long-term Knockdown of Plasminogen in Mice and Dogs using siRNA: Assessment of Phenotype and Toxicity

A.W Strilchuk^1,2, J. Leung^1,2, W.S Hur³, S. Abrahams³, L.M Silva⁴, T.H Bugge⁴, P.R Cullis¹, M.J Flick³, T.C Nichols³, C.J Kastrup^1,2
Abstract Number: PB0376

Correlation between Plasma Levels, Anti-FXa Activity and Coagulation Parameters in Real-world Patients on Treatment with Edoxaban

M. Corrochano¹, R. Acosta-Isaac¹, S. Mojal¹, N. Grabalosa¹, M. Plaza¹, B. Jiménez¹, J.C. Souto¹, MACACOD Proyect
Abstract Number: LPB0120

Correlation between Procoagulant Platelets and Hypercoagulability in Lung Cancer Patients

M. Schreuder^1,2, E.E. Ramsay^1,2, H. Campbell³, J. Simes¹, M. Boyer⁴, A. Joshua^5,6,7, V. Chin^5,6,7, J. Young^8,9,10, B. Brown², V.M. Chen^3,11, P.J. Hogg^2,12
Abstract Number: PB0750

Correlation between Serum PDGF-CC Levels with Clinical Stage of Colorectal Cancer

E. Sundarita¹, M. Syahrir¹, N. Djamaludin¹, Y.D. Andayani¹, Z. Zulaikha¹, E. Syahriana¹
Abstract Number: PB0354

Correlation between the Rosner Index with the Etiological Diagnosis of the Prolongation of the Activated Partial Thromboplastin Time (aPTT) in Asymptomatic Presurgical Patients

B.L. Diaz Jordan¹, V.B. Yepez Espinales¹, G. Lopez de la Osa Garcia¹
Abstract Number: PB0264

Correlation of Coagulation Parameters with Prognosis of COVID-19

O. Smirnova¹, O. Matvienko¹, N. Korsakova¹, A. Lerner², T. Shvedova², O. Golovina¹, L. Papayan¹
Abstract Number: PB0947

Correlation of VWF:Ab to VWF:Ag Ratio and Abnormal VWF Multimer Pattern

M. Stuart¹, D. Chen¹, N. Heikal¹, R. Pruthi¹
Abstract Number: PB0678

Cost-effectiveness Analysis of the Brazilian Immune Tolerance Induction Protocol with Recombinant Factor VIII and Prophylaxis with Bypassing Agents or Emicizumab

R.M. Camelo¹, S.M. Rezende¹, J. Álvares-Teodoro²
Abstract Number: PB0341

Cost-effectiveness of a Stepwise versus an All-in-One Approach to Diagnose Mild Bleeding Disorders

F. Heubel-Moenen¹, L. Ansems¹, P. Verhezen², R. Wetzels², R. Straat², Y. Henskens², E. Beckers³, M. Joore⁴
Abstract Number: PB0600

Cost-effectiveness of rFVIII Single-chain in an Italian Population of Hemophilia A Patients: The Veneto Experience

E. Zanon¹, S. Pasca¹, P. Radossi², E. Bonetti³, A.C. Giuffrida³, A. Tosetto⁴
Abstract Number: PB1050

Could the Adjusted Version of the Global Antiphospholipid Syndrome Score (aGAPSS) Be a Useful Tool to Select Patients with Primary Obstetric Antiphospholipid Syndrome (POAPS) for Primary Thromboprophylaxis with Aspirin?

S. Udry¹, F. Aranda¹, S. Perés Wingeyer¹, S. Stephanie Morales Perez², C. Belizna³, J. Alijotas-Reig⁴, E. Esteve-Valverde², D.S. Fernández Romero⁵, J.O. Latino⁵, G. de Larrañaga¹
Abstract Number: PB1097

Could Thromboprophylaxis Influence the Clinical Course of Patients with Active Cancer? Preliminary Results from the ACT4CAT Study

N. Tsoukalas¹, A. Christopoulou¹, E. Timotheadou¹, A. Koumarianou¹, I. Athanasiadis¹, S. Peroukidis¹, G. Samelis¹, A. Psyrri¹, N. Kapodistrias¹, C. Kalofonos¹, C. Andreadis¹, A. Ardavanis¹, E. Samantas¹, A. Bokas¹, V. Barbounis¹, N. Kentepozidis¹, D. Mavroudis¹, A. Athanasiadis¹, P. Papakotoulas¹, I. Boukovinas¹
Abstract Number: PO138

COVID-19 and Coagulation Abnormalities Diagnostic Dilemma

N. Odeleye¹, N. Kennedy¹, P. Shinde¹
Abstract Number: NUR 01.2

COVID-19 and its Impact on the Pediatric Bleeding Disorders Population: Soaring BMIs

V. Bouskill¹, D. Tetzlaff¹, C. Malcolmson¹, C. Wakefield¹, M. Carcao¹
Abstract Number: PB0194

COVID-19 and Patients with Hemorrhagic Congenital Disease: Experience from Regional Heamophilia Treatment Center of Strasbourg (France)

M. Wald¹, O. Feugeas¹, D. Desprez¹
Abstract Number: PB0178

COVID-19 Diagnosis and its Impact on Thrombotic Risk in a Cohort of Consecutive Patients Hospitalized due to Severe Acute Respiratory Syndrome

A. Coy Canguçu¹, G. Aparecida Locachevic², J.C. Silva Mariolano², K.H. de Oliveira Soares², J.D. Oliveira², C. de Oliveira Vaz², G. Vieira Damiani², B. Mazetto², J. Annichino-Bizzacchi², E. V. de Paula², F. Andrade Orsi²
Abstract Number: PB0179

COVID-19 Infection is Associated with Antibody-mediated Procoagulant Platelets: Data from an Observational Study

K. Althaus^1,2, I. Marini¹, J. Zlamal¹, H. Häberle³, M. Mehrländer³, L. Pelzl¹, A. Singh¹, S. Hammer², M. Bitzer⁴, N. Malek⁴, D. Rath⁵, H. Bösmüller⁶, M. Gawaz⁵, P. Rosenberger³, T. Bakchoul^1,2
Abstract Number: PB0188

COVID-19 Pneumonia Worse Prognosis Related to Lupus Anticoagulant Transient Positive Test

J.M. Ceresetto¹, S. Rivarola², C. Duboscq¹, M. Carreras¹, A. Cantillo¹, L. Zapata¹, K. Oliveros¹, A. Avila¹, C. Sernaque¹, M. Quarchioni¹, N. Flegler¹, S. Palmer¹, G. Stemmelin¹
Abstract Number: PB0183

COVID-19 Related Abnormalities in the Hematologic Characteristics among Inpatient Children. Results of the PICNIC Registry

S. Tehseen¹, J. Robinson², S. Williams³, L. Lieberman⁴, PICNIC Paediatric Investigator Collaborative Network on Infections in Canada
Abstract Number: PB0177

COVID-19 Vaccination and Anticoagulation: Potential Effects on Anticoagulation Control in Patients Using Vitamin K Antagonists

C. Visser¹, J.S. Biedermann¹, M.C. Nierman², F.J.M. van der Meer³, S.C. Cannegieter^3,4, W.M. Lijfering⁴, M.J.H.A. Kruip¹
Abstract Number: PB0165

COVID-19-Related Thrombosis in Japan: Results of a Questionnaire-based Survey in 2020

H. Horiuchi¹, E. Morishita², T. Urano³, K. Yokoyama⁴, - The Questionnaire-Survey Joint Team on the COVID-19-Related Thrombosis^5,6,7
Abstract Number: OC 29.3

CRISPR Edited Megakaryocytes for Rapid Screening of Platelet Gene Functions

E. Montenont¹, S. Bhatlekar¹, S. Jacob¹, Y. Kosaka¹, B. Manne¹, O. Lee¹, I. Parra-Izauierdo², E. Tugolukova¹, N. Tolley¹, M. Rondina¹, P. Bray¹, J. Rowley¹
Abstract Number: PB0255

Cross-talk between the Inflammatory Response and Coagulopathy: Single-center Report

Y.B. Tor¹, S. Kalayoglu Besisik², M. Ozbalak², M. Kose¹, A. Medetalibeyoglu¹, N. Senkal¹, A. Cagatay³, S. Simsek Yavuz³, A. Gul⁴, M. Erelel⁵, F. Esen⁶, T. Tukek¹
Abstract Number: OC 01.1

Crosstalk between the Complement Pathway and the Contact Activation System of Coagulation: Activated Factor XI Neutralizes Complement Factor H

C. Puy¹, J. Pang¹, S.E Reitsma¹, C.U Lorentz¹, E.I Tucker¹, D. Gailani², A. Gruber¹, F. Lupu³, O. J.T. McCarty¹
Abstract Number: OC 42.4

Cryoprecipitate Transfusion Significantly Decreases the Rate of Plasmin Generation in Trauma Patients

G.B Morrow^1,2, M.SA Carlier², S. Dasgupta², F.B Craigen², C.S Whyte², J. Winearls³, M.A Laffan^4,5, N.J Mutch², N. Curry^1,5
Abstract Number: OC 26.2

Cryoprecipitate, and Not Fibrinogen Concentrate, Enhances Early Clot Formation in an in vitro Microfluidic Model of Dilutional Coagulopathy

S. Shea¹, K. Thomas¹, P. Spinella¹
Abstract Number: OC 05.1

Crystal Structure of Factor IXa with an Anticoagulant Aptamer Bound to an Allosteric Site

V. Kolyadko¹, J. Layzer², B. Sullenger², S. Krishnaswamy^1,3
Abstract Number: OC 09.2

Crystal Structure of the von Willebrand Factor A1 Domain – Caplacizumab Complex

A. Brown¹, J. Emsley¹, N. Arce², R. Li²
Abstract Number: PB1105

Cumulative Incidence of Recurrent Venous Thromboembolism by Cancer and Provoking Status – A Population-based Study

K. Ding¹, L. Ford¹, A. Wendelboe¹, A. Adamski², N. Reyes², K. Abe², G. Raskob¹
Abstract Number: PB1028

Curcumin Inhibits Platelets by Activation of Adenosine A2 Receptor and cAMP/PKA Pathway

N. Rukoyatkina¹, N. Al Arawe², S. Gambaryan¹, V. Shpakova¹